Diabetic Kidney Disease — Semaglutide Flows into the Mainstream-Reference-Cited by-同舟云学术

Diabetic Kidney Disease — Semaglutide Flows into the Mainstream

Published:2024-07-11 Issue:2 Volume:391 Page:178-179
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Herrington William G.¹^ORCID,Haynes Richard¹

Affiliation:

1. From the Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.

Publisher

Massachusetts Medical Society

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMe2406408

Reference10 articles.

1. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease

2. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

3. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis

4. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes

5. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chez les sujets avec diabète de type 2 et insuffisance rénale chronique, est-ce que le sémaglutide prévient l’insuffisance rénale terminale, la perte significative de fonction rénale ou le décès de causes rénales ou cardiovasculaires comparativement au placebo, tout en étant sécuritaire ?;La Revue de Médecine Interne;2024-08